当前位置:网站首页 > 学术论文 > > 2023 ASCO前瞻 | 泌尿肿瘤领域重磅研究及中国研究一览

2023 ASCO前瞻 | 泌尿肿瘤领域重磅研究及中国研究一览

文章来源:武汉配发器械网浏览次数:1679
核心提示:一年一度的全球肿瘤界盛会-美国临床肿瘤学会(ASCO)年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模大、学术水平高、具权威的临床肿瘤学会议,致力于癌症的预防、治疗和改善患者管理,以展


一年一度的全球肿瘤界盛会-美国临床肿瘤学会(ASCO)年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模大、学术水平高、具权威的临床肿瘤学会议,致力于癌症的预防、治疗和改善患者管理,以展示肿瘤的基础研究和临床新研究为特点,讨论当前国际先进的治疗方法。医脉通精选了泌尿肿瘤领域Oral Abstract Session部分的13项重磅研究及Poster Session部分入选的8项中国研究,小编带您先睹为快。

 

口头报告专场(Oral Abstract Session

前列腺/睾丸/阴茎肿瘤

 

摘要号:LBA5000

标题:Prostate irradiation in men with de novo, low-volume, me[x]tastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.

报告人:Alberto Bossi

 

摘要号:5004

标题:TALAPRO-2: Phase 3 study of talazoparib (TALA) enzalutamide (ENZA) versus placebo (PBO) ENZA as first-line (1L) treatment for patients (pts) with me[x]tastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.

报告人:Karim Fizazi

 

摘要号:5005

标题:LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with me[x]tastatic castration resistant prostate cancer (mCRPC).

报告人:Shahneen Sandhu

 

口头报告专场(Oral Abstract Session

LBA4619的演示及讨论

 

摘要号:LBA4619

标题:Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or me[x]tastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).

报告人:Yohann Loriot

 

口头报告专场(Oral Abstract Session

肾脏/膀胱肿瘤

 

摘要号:LBA4500

标题:Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in me[x]tastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.

报告人:Toni K. Choueiri

 

摘要号:LBA4501

标题:Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.

报告人:Brian I. Rini

 

摘要号:4502

标题:Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).

报告人:Thomas E. Hutson

 

摘要号:4503

标题:Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo) platinum/gemcitabine (plt/gem) vs placebo plt/gem in patients (pts) with me[x]tastatic urothelial carcinoma (mUC): Updated data from the IMvigor130 OS final analysis.

报告人:Enrique Grande

 

摘要号:4504

标题:Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA CET) for patients (pts) with me[x]tastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study.

报告人:Arlene O. Siefker-Radtke

 

摘要号:4505

标题:Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or me[x]tastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up.

报告人:Shilpa Gupta

 

摘要号:4506

标题:Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial.

报告人:Robert J. Motzer

 

摘要号:LBA4507

标题:Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial.

报告人:Christian Pfister

 

摘要号:LBA4508

标题:SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.

报告人:Seth P. Lerner

 

壁报专场(Poster Session

前列腺/睾丸/阴茎肿瘤

 

摘要号:5057

海报号:151

标题:Tumor heterogeneity and treatment response assessment using next generation imaging and liquid biopsy in patients with me[x]tastatic castration resistant prostate cancer receiving abiraterone (ANGELA): A single-center prospective observational trial.

报告人:朱耀,复旦大学附属肿瘤医院

 

摘要号:5065

海报号:159

标题:Deutenzalutamide, an oral deuterated androgen receptor inhibitor, vs placebo for patients with mCRPC who have experienced treatment failure with abiraterone and docetaxel: Results of the HC-1119-04 phase 3 trial.

报告人:叶定伟,复旦大学附属肿瘤医院

 

壁报专场(Poster Session

肾脏/膀胱肿瘤

 

摘要号:4521

海报号:13

标题:Effect of KDR mutations on efficacy of immune checkpoint inhibitors in patients with bladder cancer.

报告人:戴洪海,山东省立医院

 

摘要号:4533

海报号:25

标题:Preliminary results from a phase II study comparing sunitinib alone or with stereotactic body radiotherapy (SBRT) for newly diagnosed oligome[x]tastatic renal cell carcinoma.

报告人:刘洋,中山大学肿瘤防治中心

 

摘要号:4543

海报号:35

标题:Immunoglobulin as a predictive biomarker for the efficacy of immune checkpoint inhibitor combined with VEGF-TKI in me[x]tastatic renal cell carcinoma.

报告人:Honglei Cui,中国医学科学院肿瘤医院

 

摘要号:4566

海报号:58

标题:Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC), combined with toripalimab in patients with locally advanced or me[x]tastatic urothelial carcinoma: An open-label phase 1b/2 study.

报告人:盛锡楠,北京大学肿瘤医院

 

摘要号:4585

海报号:77

标题:Final analysis results from a multicenter clinical study of tislelizumab combined with gemcitabine and cisplatin as neoadjuvant therapy in patients with cT2-T4aN0M0 MIBC.

报告人:林天歆,中山大学孙逸仙纪念医院

 

-->

政策法规更多 >>

三部门发文:不能变相取消县级中医医院,应提升其电子病历应用能力

三部门发文:不能变相取消县级中医医院,应提升其电子病历应用能力

三部门发文,明确不能变相取消县级中医医院,还要提...

今年打击骗保专项整治工作启动
《健康医疗数据合规流通标准》正式发布!
国家卫生健康委要求—— 推进加速康复外科诊疗模式应用
山西弘扬爱国卫生新风尚
国家卫生健康委等14部门联合发文要求—— 重点整治医药领域突出腐败问题
DRG付费与耗材带量采购联动实施
《老年人疫苗接种科普手册》发布
安徽省卫健委印发《2023年随机监督抽查实施方案》

新品动态更多 >>

事关癌症检测与治疗!我国科研人员有新成果

事关癌症检测与治疗!我国科研人员有新成果

核心提示:GQDNT是一种模块化自组装纳米粒子,...

新型CRISPR/Cas9 mRNA脂质纳米颗粒治疗乙型肝炎
新研究发现不依赖于细菌感染即可修复伤口的机制!
重大进展!新研究发现不依赖于细菌感染即可修复伤口的机制!
造血干细胞体外扩增有新策略
聚焦微生物组生态系统疗法(MET)开发
新型凝胶可完全治侵袭性脑肿瘤
Sotorasib治疗KRAS p.G12C基因突变胰腺癌新进展
慢性偏头痛新药获FDA批准!慢性偏头痛患者福音

热门关键词

床头柜 麻醉车 护理车

热门产品